180 Life Sciences (ATNF) announced that the United States Patent and Trademark Office has issued an official Notice of Allowance for U.S. Patent Application No. 17/556,584, covering a novel method for preventing or reducing Post-Operative Cognitive Dysfunction. The newly allowed patent covers a method for reducing POCD – particularly POCD manifested as delirium – by administering an anti-Human tumor necrosis factor Alpha monoclonal antibody to the patient in a therapeutically effective amount commencing just before and during the surgical procedure.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATNF:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue